Danaher Corporation
$ 235.99
-1.63%
16 Jan - close price
- Market Cap 168,981,021,000 USD
- Current Price $ 235.99
- High / Low $ 240.42 / 235.75
- Stock P/E 48.56
- Book Value 72.31
- EPS 4.86
- Next Earning Report 2026-01-28
- Dividend Per Share $1.23
- Dividend Yield 0.51 %
- Next Dividend Date 2026-01-30
- ROA 0.04 %
- ROE 0.07 %
- 52 Week High 256.62
- 52 Week Low 170.19
About
Danaher Corporation (DHR) is a leading American diversified conglomerate headquartered in Washington, D.C., with a strong focus on Life Sciences, Diagnostics, and Environmental and Applied Solutions. Renowned for its commitment to innovation and cutting-edge technology, Danaher plays a crucial role in enhancing healthcare outcomes and optimizing industrial processes worldwide. The company's operational excellence and strategic investments position it well for sustainable growth, making it a compelling opportunity for institutional investors seeking exposure to high-growth sectors within the healthcare and industrial markets.
Analyst Target Price
$261.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-21 | 2025-07-22 | 2025-04-22 | 2025-01-29 | 2024-10-22 | 2024-07-23 | 2024-04-23 | 2024-01-30 | 2023-10-24 | 2023-07-25 | 2023-04-25 | 2023-01-24 |
| Reported EPS | 1.89 | 0.77 | 1.88 | 1.49 | 1.71 | 1.72 | 1.92 | 2.09 | 2.02 | 2.05 | 2.36 | 2.87 |
| Estimated EPS | 1.72 | 1.18 | 1.64 | 1.73 | 1.57 | 1.57 | 1.71 | 1.91 | 1.88 | 2.02 | 2.26 | 2.55 |
| Surprise | 0.17 | -0.41 | 0.24 | -0.24 | 0.14 | 0.15 | 0.21 | 0.18 | 0.14 | 0.03 | 0.1 | 0.32 |
| Surprise Percentage | 9.8837% | -34.7458% | 14.6341% | -13.8728% | 8.9172% | 9.5541% | 12.2807% | 9.4241% | 7.4468% | 1.4851% | 4.4248% | 12.549% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-01-28 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 2.14 |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-30 | 2025-10-31 | 2025-07-25 | 2025-04-25 | 2025-01-31 | 2024-10-25 | 2024-07-26 | 2024-04-26 | 2024-01-26 | 2023-10-27 |
| Amount | $0.32 | $0.32 | $0.32 | $0.32 | $0.27 | $0.27 | $0.27 | $0.27 | $0.24 | $0.27 |
Next Dividend Records
| Dividend per share (year): | $1.23 |
| Dividend Yield | 0.51% |
| Next Dividend Date | 2026-01-30 |
| Ex-Dividend Date | 2025-12-26 |
Recent News: DHR
2026-01-19 05:58:44
The global Gas Chromatography Systems Market is projected to reach US$7,203.59 million by 2032, growing at a CAGR of 8.8% from US$3,668.75 million in 2024. This growth is driven by technological advancements, expanding applications in various industries like pharmaceuticals and environmental monitoring, and stringent governmental regulations. North America leads the market with a 35% share, while key players include Thermo Fisher Scientific and Agilent Technologies.
2026-01-19 02:00:32
Revvity (RVTY), a life-science and diagnostics business spun off from PerkinElmer, has shown quiet outperformance in the healthcare sector. The company is focusing on precision medicine, clinical diagnostics, and advanced research tools, leading to a steady uptrend in its stock, which analysts believe could be a prelude to a larger breakout. Despite some concerns about macro risks, Wall Street has generally warmed to Revvity's strategy, with many analysts recommending a Buy or Overweight rating and moderate upside targets, based on improved organic growth and disciplined capital allocation.
2026-01-18 23:56:36
Analysts have maintained a buy rating for Danaher Corporation (DHR), indicating an optimistic outlook for the company's performance. The consensus among financial experts suggests potential upside for DHR stock by 2026. This positive sentiment reflects confidence in Danaher's future growth prospects.
2026-01-18 14:19:21
Tred Avon Family Wealth LLC recently acquired 5,447 shares of Danaher Corporation (NYSE:DHR) during the third quarter, valued at approximately $1.08 million. Despite this new institutional investment, several insiders, including Director Teri List and SVP Georgeann Couchara, have sold significant amounts of DHR stock. Analysts maintain a "Moderate Buy" rating for Danaher with a consensus price target of $252.83, following the company's Q3 earnings beat.
2026-01-18 13:20:28
Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Danaher Corporation (NYSE: DHR) stock on December 18th, 2025. This sale was part of several transactions where she also sold shares in other major companies like Texas Instruments, UnitedHealth Group, and Walmart on the same date. The article also provides a financial overview of Danaher, including its price performance, recent earnings, dividend announcement, institutional ownership, and analyst ratings, noting a "Moderate Buy" consensus.
2026-01-18 12:35:28
QRG Capital Management Inc. reduced its stake in Danaher Corporation (NYSE:DHR) by 30% in the third quarter, selling 13,553 shares and retaining 31,572 shares valued at $6.26 million. Despite this institutional selling, Wall Street analysts maintain a "Moderate Buy" consensus with an average target price of $252.83, and several other institutional investors increased their holdings. Insiders have also been net sellers, offloading 30,248 shares worth $6.61 million in the last 90 days, though still owning 11.10% of the company.
